Completed PHASE2 INTERVENTIONAL NCT00035516

A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy

Sponsor: R-Pharm

Conditions Carcinoma, Non-small-cell Lung

Interventions Epothilone

Updated 5 times since 2017 Last updated: Feb 9, 2016 Started: Feb 28, 2001 Primary completion: Apr 30, 2004 Completion: Apr 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00035516, this PHASE2 trial focuses on Carcinoma, Non-small-cell Lung and remains completed. Sponsored by R-Pharm, it has been updated 5 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

R-Pharm

Data source: R-Pharm

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Birmingham, United States , Burlington, United States , Chapel Hill, United States , Chicago, United States , Columbia, United States , Lebanon, United States , Louisville, United States , Madison, United States , Miami Beach, United States and 5 more locations